ADH-503;ADH503;ADH 503
| 中文名稱 | ADH-503;ADH503;ADH 503 |
|---|---|
| 中文同義詞 | (Z)-4-[5-(3-芐基-2,4-二氧代噻唑烷-5-亞甲基)-呋喃-2-基]-苯甲酸 (2-羥基-乙基)-三甲基銨鹽;LEUKADHERIN-1 CHOLINE SALT;化合物ADH-503;ADH-503(鎓鹽);2-羥基-N,N,N-三甲基乙烷-1-氨基鎓(Z)-4-(5-((3-芐基-4-氧代-2-硫代噻唑烷-5-亞基)甲基)呋喃-2-基)苯甲酸鹽;化合物ADH-503,10 MM DMSO 溶液 |
| 英文名稱 | ADH-503 |
| 英文同義詞 | ADH 503;ADH503;ADH-503;ADH-503;ADH503;ADH 503;ADH-503 - Leukadherin-1 choline salt;ADH-503 [(Z)-Leukadherin-1 choline;2-Hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate;tumor-infiltrating,CD11b,ADH-503,Inhibitor,tumorassociated,dendritic,immunosuppressive,macrophages,repolarization,allosteric,inhibit,Complement System,ADH503,orally,ADH 503 |
| CAS號 | 2055362-74-6 |
| 分子式 | C27H29N2O5S2+ |
| 分子量 | 525.66 |
| EINECS號 | |
| 相關(guān)類別 | 制劑-激動劑 |
| Mol文件 | 2055362-74-6.mol |
| 結(jié)構(gòu)式 |  |
ADH-503;ADH503;ADH 503 性質(zhì)
| 儲存條件 | Store at -20°C |
|---|---|
| 溶解度 | 二甲基亞砜：21.43 mg/mL（40.85 mM） |
| 形態(tài) | 固體 |
| 顏色 | 棕至紅棕色 |
CD11b
ADH-503 ((Z)-Leukadherin-1 choline; 4 μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b + cells and subsets of CD11b + monocytes, granulocytes, eosinophils, and macrophages.
ADH-503 ((Z)-Leukadherin-1 choline; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
ADH-503 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC
0-t
in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively.
| Animal Model: | KPC mice [p48-CRE/Lox-stop-Lox(LSL)-Kras G12D /p53 flox/flox ] |
| Dosage: | 30, 60, or 120 mg/kg |
| Administration: | Oral gavage; 60 days |
| Result: | Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival. |
| Animal Model: | Male rats |
| Dosage: | 30, 100 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral gavage twice a day; on days 1 and 5 |
| Result: | Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC 0-t in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively. |
安全信息
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2025/02/08 | HY-15701B | ADH-503;ADH503;ADH 503 ADH-503 | 2055362-74-6 | 5mg | 550元 |
| 2025/02/08 | HY-15701B | ADH-503;ADH503;ADH 503 ADH-503 | 2055362-74-6 | 10mM * 1mLin DMSO | 635元 |